Elan Corporation plc / Theravance Inc. (royalty interest)
2013 · Asset Purchase · $1.0B · Terminated
Announcement Sentiment
50
Neutral / mixed
Elan agreed $1B cash for 21% of Theravance's royalties on its GSK-partnered respiratory programs (Breo, Anoro, vilanterol, MABA); deal ultimately voted down by Elan shareholders amid Royalty Pharma takeover battle.